Pricing and Order Risks from Competitors’ Aggressive Discounting and Restrained Investment by Medical Facilities
First written in FY2016. 9 of 15 entries say "Worsened", first in FY2017-Q2. Latest entry: 2026-08-05.
Techno Medica moved to the "Worse" side of this theme in 2016.
1 other company's latest entry also says "Worsened".
- 2026-08-05WorsenedEarnings
「Competition remains intense and the market environment difficult both domestically and overseas. Domestic sales amounted to ¥61,878 thousand, down 8.0% year on year, while overseas sales amounted to ¥41,616 thousand, down 22.9% year on year.」
For specimen testing equipment, the statement indicates that the highly competitive market environment continues and that sales declined both domestically and overseas. - FY2026WorsenedAnnual report
「Revenue from specimen testing equipment for the fiscal year was ¥527.891 million, down 15.1% from the previous fiscal year. In Japan, revenue was ¥295.627 million, down 24.7%, as competition among blood gas analyzer suppliers intensified.」
Competition in the domestic market for blood gas analyzers has become more intense, and domestic revenue declined 24.7% year on year. The deterioration in the competitive environment is reflected in sales results. - 2026-05-11WorsenedEarnings
「In the domestic market, as the competitive environment for blood gas analyzers became increasingly challenging, net sales amounted to ¥295,627 thousand, down 24.7% year on year.」
The statement indicates worsening competition and declining sales in the domestic market for specimen testing equipment. - FY2024WorsenedAnnual report
「In overseas markets, revenue fell substantially below the previous fiscal year's level due to the postponement of projects for China and South Korea and intensifying competition with other companies in various countries, resulting in revenue of ¥155,790 thousand, down 44.6% year on year.」
In overseas markets, projects for China and South Korea were postponed and competition with other companies intensified, resulting in a 44.6% year-on-year decline in overseas revenue from the blood collection tube preparation equipment and systems business. Deterioration in the competitive and order environment is reflected in full-year results. - FY2023RestatedAnnual report
「Although the company's blood collection tube preparation equipment and systems have a domestic market share of around 90%, the company's sales could be affected by the specifications and selling prices of new products introduced by competitors.」
While maintaining a high domestic market share, the company continues to disclose the risk that competitor specifications and selling prices could affect sales. Its responses include contactless operation, shorter waiting times and the addition of optional products. - FY2023-Q3WorsenedAnnual report
「Overseas revenue was ¥169,860 thousand, down 29.0% year on year, due mainly to a decrease in projects resulting from intensifying competition with other companies.」
The company explicitly identifies a decrease in projects resulting from intensifying competition with other companies in overseas markets, and overseas revenue from its blood collection tube preparation equipment and systems declined 29.0% year on year. Order risks from competition and pricing have worsened in actual results. - FY2023-Q2WorsenedAnnual report
「Overseas revenue was ¥89,476 thousand, down 56.9% year on year, amid a challenging market environment in which recovery from the impact of COVID-19 has been slow across all regions and competition with other companies has intensified.」
The company explicitly identifies intensifying competition with other companies in overseas markets, and overseas revenue from its blood collection tube preparation equipment and systems declined 56.9% year on year. - FY2022RestatedAnnual report
「Although the company's blood collection tube preparation equipment and systems have a domestic market share of around 90%, the company's sales could be affected by the specifications and selling prices of new products introduced by competitors.」
While maintaining a high market share, the company continues to disclose the risk that competitor specifications and selling prices could affect sales. - FY2020WorsenedAnnual report
「Although intensifying competition, including price competition, is considered unavoidable in the medical equipment industry in which the company operates, the company will continue to steadily pursue activities to identify needs in medical settings accurately and create new value even in such an environment.」
The company recognizes that intensifying competition, including price competition, is unavoidable in the medical equipment industry, and explicitly identifies the severity of the competitive environment in addition to the previously disclosed risks of competitor discounting and price reductions. - FY2019RestatedAnnual report
「However, user needs are diverse, and aggressive discounting by competitors could affect sales, including by forcing the company to lower its planned selling prices or abandon orders.」
The company continues to disclose the risk of lower selling prices and abandoned orders resulting from aggressive competitor discounting. - FY2018RestatedAnnual report
「However, user needs are diverse, and aggressive discounting by competitors could affect sales, including by forcing the company to lower its planned selling prices or abandon orders.」
While seeking to maintain selling prices through product differentiation and brand building, the company continues to disclose the risk of price reductions and abandoned orders resulting from aggressive competitor discounting. - FY2018-Q3RestatedAnnual report
「In a challenging market environment where competition with other companies continues, domestic revenue was ¥271,450 thousand, down 0.5% year on year, and overseas revenue was ¥63,504 thousand, down 31.2% year on year.」
The company has reconfirmed the challenging market environment in which competition with other companies continues in the specimen testing equipment field. No further deterioration in the competitive environment or extent of price reductions is described. - FY2017WorsenedAnnual report
「As consolidation and closures of medical facilities continue, requests for further price reductions and competition among manufacturers are expected to intensify.」
The company forecasts that requests for price reductions and competition among manufacturers will intensify further against a backdrop of consolidation and closures of medical facilities. - FY2017-Q2WorsenedAnnual report
「Declining revenue at medical institutions will inevitably affect the entire clinical testing market, which is the company's primary target market, and requests for further price reductions and competition among manufacturers are expected to intensify.」
The company forecasts that requests for price reductions and competition among manufacturers will intensify further, and its recognition of risk to the pricing and order environment has strengthened. - FY2016First statedAnnual report
「However, user needs are diverse, and aggressive discounting by competitors could affect sales, including by forcing the company to lower its planned selling prices or abandon orders.」
While maintaining a high market share, the company identifies the possibility that competitor discounting and restrained investment by medical facilities could affect pricing and orders.